Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis.
CONCLUSIONS: CCBs did not increase all-cause mortality incidence in patients with CKD though they displayed weaker renoprotective, compared to ACEIs or ARBs therapy. Our results suggest the combination of a CCB and an ACEI or ARB should be a preferable antihypertensive therapy in patients with CKD, considering their higher effect in decreasing blood pressure and fewer adverse metabolic problems caused.
PMID: 27055479 [PubMed - as supplied by publisher]
Source: Renal Failure - Category: Urology & Nephrology Tags: Ren Fail Source Type: research
More News: Calcium | Chronic Kidney Disease | Clinical Trials | Databases & Libraries | Renal Failure | Urology & Nephrology